SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) | Delaware | 85-2786970 | | --- | --- | | (State or other juris ...

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $110 million for Q4 2023, compared to a net income of $87 million for Q4 2022. For the full year, the GAAP net loss was $138 million, down from a net income of $491 million in 2022 [15][85] - Adjusted EBITDA for Q4 2023 was $21 million, with an adjusted EBITDA margin of 28%, exceeding expectations due to higher-than-anticipated revenues [12][112] - The company ended 2023 with $575 million in cash and $533 million in long-term debt, resulting in a net cash position of $42 million [16] Business Line Data and Key Metrics Changes - The Nucleic Acid Production segment generated $59 million in revenue for Q4 2023, with an adjusted EBITDA of $24 million, reflecting a margin of 41% [18] - The Biologics Safety Testing segment reported revenues of $15 million in Q4 2023, with an adjusted EBITDA of $12 million, resulting in a margin of 76% [88] - For the full year, the Nucleic Acid Production segment had revenues of $225 million and adjusted EBITDA of $83 million, a margin of 37% [115] Market Data and Key Metrics Changes - The company identified over 350 programs utilizing CleanCap, with more than 100 new programs in the last 12 months, indicating strong market interest [103] - The FDA approved nearly 50% more novel drugs in 2023 than in 2022, suggesting a favorable regulatory environment for the company's products [77] Company Strategy and Development Direction - The company is entering a new phase referred to as Maravai 3.0, focusing on innovation across the mRNA production workflow and diversifying its business for sustainable growth [68][119] - The strategy includes fostering key academic and industry partnerships to enhance innovation and accelerate market adoption of the latest technology [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the guidance range for 2024, noting a higher percentage of revenue recognized or committed compared to the previous year [25] - The company anticipates a return to growth in 2024, driven by a diversified customer base and increased binding commitments from customers [96][102] Other Important Information - The company plans to reduce capital expenditures to $30 million to $35 million in 2024, following the completion of facility investments [118] - The company will no longer estimate COVID-related CleanCap in its guidance, recognizing its use across various applications [89] Q&A Session Summary Question: Can you discuss the demand environment over the last 3 to 6 months? - Management noted a shift towards a more diversified customer base and a willingness to make binding commitments again, which is a positive change [96] Question: What is the anticipated decline in contractual commitments for 2024? - Management confirmed that there is a $50 million contractual commitment for 2024, down from $60 million to $65 million in 2023, and emphasized the importance of modeling this correctly for future projections [33] Question: Can you provide additional comments on the FUJIFILM partnership? - Management highlighted the strategic importance of the partnership, noting it could be meaningful but depends on customer signings as a CDMO [56]

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation SAN DIEGO, Calif., — February 22, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2023, together with other business updates. Recent ...

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted patents by the China National Intellectual Property Administration (CNIPA) and the Canadian Intellectual Property Office (CIPO). Patent numbers ZL 2023 1 0734863.0 and CA 2999274 are related to TriLink’s CleanCap® technology for the co-transcriptional capping of mRNAs – a critical component of the production of synthetic mRN ...

Maravai LifeSciences (MRVI) FY 2023 Conference November 16, 2023 09:00 AM ET Speaker0 Good afternoon. Thanks for being here at the last session of our London conference. We're very excited to have Maribai Life Sciences with us today here to tell us more about the story before we jump into some Q and A, CEO, Trey Martin as well as CFO, Kevin Hurti. Turn it over to Trey. Speaker1 All right. Thank you. Thanks for being here in person. I know it sounds like we're at the tail end of this conference. And also tha ...

Q3 2023 Financial Performance - Revenue reached $67 million[7] - Adjusted EPS was negative, at ($0.01) per share[7] - Adjusted EBITDA stood at $12 million[16] - Base Nucleic Acid Production (NAP) revenue totaled $36 million[7] - NAP revenue reached $51 million[16] - Biologics Safety Testing (BST) revenue was $16 million[33] Updated 2023 Financial Guidance - Revenue guidance was updated to $275 to $285 million[51] - CleanCap® COVID-19 revenue is projected at $61 million[51] - Adjusted EPS guidance was updated to ($0.01) to $0.01 per share[51] - Adjusted EBITDA guidance was updated to $55 to $60 million[51] Cost Savings and Restructuring - The company is targeting at least $30 million in annualized cost savings through workforce and expense reductions[19,35] - A workforce reduction of approximately 15% is planned, targeting $23 million in savings[19] - Non-labor expense reductions are expected to yield $7 million in savings[19]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-2786970 (I.R.S. Employer Identification No ...

Financial Performance - Q2 2023 revenue was $69 million[56] - Adjusted EBITDA for Q2 2023 was $9.1 million, with an Adjusted EBITDA Margin of 13%[56] - The company has $580 million in cash and $536 million in long-term gross debt[17, 37] - Adjusted Free Cash Flow was -$18 million in Q2 2023[58] Segment Performance - Nucleic Acid Production revenue was $53 million, representing 77% of total revenue, with $14 million in Adjusted EBITDA; CleanCap® from COVID-19 contributed $11.6 million[60] - Biologics Safety Testing revenue was $16 million, representing 23% of total revenue, with $10 million in Adjusted EBITDA[40, 61] Guidance Update - Updated 2023 revenue guidance is $300 to $325 million, a decrease of $108 million from prior guidance[74] - CleanCap® COVID-19 revenue guidance is $65 million, a decrease of $35 million from prior guidance[74] - Updated Adjusted EPS guidance is $0.04 to $0.08 per share, a decrease of $0.24 per share from prior guidance[74] - Updated Adjusted EBITDA guidance is $70 to $80 million, a decrease of $90 million from prior guidance[74] Strategic Initiatives - Trey Martin has taken over as Maravai's next CEO [9] - The company executed three new license and supply agreements in 1H 2023[16]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-2786970 (I.R.S. Employer Identification No.) Re ...